New smart drug targets cancer cells in advanced tumors and lung cancer
NCT ID NCT07439094
First seen Feb 28, 2026 · Last updated May 16, 2026 · Updated 11 times
Summary
This study tests a new drug called CKD-703 for people with advanced solid tumors or a type of lung cancer (non-small cell lung cancer) that has not responded to standard treatments. CKD-703 is designed to deliver a powerful chemotherapy drug directly to cancer cells that have a specific marker (c-Met), aiming to kill them while reducing harm to healthy cells. The trial has three parts and will enroll about 140 adults to check safety, side effects, and how well the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Gabrail Cancer Center
RECRUITINGOhio City, Ohio, 44718, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.